Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium

Author's Avatar
Feb 02, 2023

Pulse+Biosciences%2C+Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced its technology will be highlighted in a poster presentation at the 28th Annual International AF Symposium meeting in Boston February 2–4.